Atyr Pharma Inc (NASDAQ: ATYR)’s stock price has dropped by -4.47 in relation to previous closing price of 5.48. Nevertheless, the company has seen a loss of -4.82% in its stock price over the last five trading days. globenewswire.com reported 2025-06-04 that Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses.
Is It Worth Investing in Atyr Pharma Inc (NASDAQ: ATYR) Right Now?
ATYR has 36-month beta value of 0.89. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATYR is 86.06M, and currently, short sellers hold a 16.00% ratio of that float. The average trading volume of ATYR on June 17, 2025 was 1.63M shares.
ATYR’s Market Performance
ATYR stock saw an increase of -4.82% in the past week, with a monthly gain of 60.09% and a quarterly increase of 35.27%. The volatility ratio for the week is 4.10%, and the volatility levels for the last 30 days are 4.24% for Atyr Pharma Inc (ATYR). The simple moving average for the past 20 days is 9.88% for ATYR’s stock, with a 59.73% simple moving average for the past 200 days.
Analysts’ Opinion of ATYR
Many brokerage firms have already submitted their reports for ATYR stocks, with Leerink Partners repeating the rating for ATYR by listing it as a “Outperform.” The predicted price for ATYR in the upcoming period, according to Leerink Partners is $16 based on the research report published on February 18, 2025 of the current year 2025.
Wells Fargo gave a rating of “Overweight” to ATYR, setting the target price at $17 in the report published on October 04th of the previous year.
ATYR Trading at 36.64% from the 50-Day Moving Average
After a stumble in the market that brought ATYR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.46% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATYR starting from Gross Jane A, who purchase 3,750 shares at the price of $4.00 back on Mar 17 ’25. After this action, Gross Jane A now owns 9,750 shares of Atyr Pharma Inc, valued at $15,000 using the latest closing price.
Broadfoot Jill Marie, the Chief Financial Officer of Atyr Pharma Inc, sale 1,254 shares at $3.78 during a trade that took place back on Feb 04 ’25, which means that Broadfoot Jill Marie is holding 31,763 shares at $4,740 based on the most recent closing price.
Stock Fundamentals for ATYR
The total capital return value is set at -0.77. Equity return is now at value -79.51, with -60.25 for asset returns.
Based on Atyr Pharma Inc (ATYR), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.79.
Currently, EBITDA for the company is -66.37 million with net debt to EBITDA at -0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.79.
Conclusion
To put it simply, Atyr Pharma Inc (ATYR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
